Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Aurobindo Pharma Business Update

Aurobindo Pharma subsidiary's Unit-I facility received an 'official action indicated' (OAI) classification from the US FDA. The company maintains there is no financial impact.

Source

BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Aurobindo Pharma Ltd: key numbers

Share price
₹1,644.80
Market cap
₹95,530 Cr
Revenue (annual)
₹33,653 Cr
Net profit (annual)
₹3,505 Cr
P/E (TTM)
24.2×Sector 46.1×
Promoter holding
51.88%+0.00% QoQ
FII holding
17.41%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Aurobindo Pharma Ltd

All →

Other business update announcements

All →